A recent report demonstrated that the type II JAK2i CHZ868, which stabilizes JAK2 in an inactive conformation, kills JAK2 mutant B-ALL cells (Wu et al. 2015). The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.